JAK1 promotes HDV replication and is a potential target for antiviral therapy.
Fiche publication
Date publication
novembre 2023
Journal
Journal of hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Pr PESSAUX Patrick, Dr VERRIER Eloi
Tous les auteurs :
Heuschkel MJ, Bach C, Meiss-Heydmann L, Gerges E, Felli E, Giannone F, Pessaux P, Schuster C, Lucifora J, Baumert TF, Verrier ER
Lien Pubmed
Résumé
Liver chronic co-infection with hepatitis B and D viruses (HBV and HDV) is the most aggressive form of chronic viral hepatitis. To date, no treatment allows efficient viral clearance, and a better characterization of virus-host interactions is required to develop new therapeutic strategies.
Mots clés
Antiviral treatment, Hepatitis D virus, Host factor, Replication
Référence
J Hepatol. 2023 11 2;: